Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Preston, Australia Clinical Trials

A listing of Preston, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (90) clinical trials

A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's

The study is designed as a multicentre, phase 1b open-label study. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with mild to moderate Alzheimer's disease and elevated blood levels of the inflammatory biomarker high sensitivity c-reactive protein (hs-CRP). XPro1595 is a ...

Phase

2.46 miles

Learn More »

A Trial of KB004 in Patients With Glioblastoma

This is a study of drug KB004 in patients with recurrent glioblastoma (GBM). Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM ...

Phase

2.79 miles

Learn More »

Pembrolizumab + CVA21 in Advanced NSCLC

Primary Objective & Hypothesis (1) Objective: To evaluate the safety of intravenous CVA21 in combination with pembrolizumab in patients with advanced NSCLC. Hypothesis Pembrolizumab in combination with intravenous CVA21 will be well tolerated in patients with advanced NSCLC. Secondary Objective & Hypothesis (1) Objective: i. To evaluate the efficacy of ...

Phase

2.79 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

This is a Phase Ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel for patients with locally advanced or metastatic triple-negative breast cancer (mTNBC) who have not previously received chemotherapy in the advanced setting. Two triplets; ipatasertib in combination with ...

Phase

3.44 miles

Learn More »

A Study of CC-95251 a Monoclonal Antibody Directed Against SIRP in Subjects With Advanced Solid and Hematologic Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B & Part C), first-in-human clinical study of CC-95251 in subjects with advanced solid & hematologic cancers. The dose escalation part (Part A) of the study will be conducted in three stages. Stage 1 will evaluate ...

Phase

3.44 miles

Learn More »

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or ...

Phase

3.44 miles

Learn More »

A Study Evaluating the Safety Pharmacokinetics and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). ...

Phase

3.44 miles

Learn More »

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

This is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor activity of MGD013 administered by IV infusion on every 2 weeks. The study consists of a Dose Escalation Phase to determine the MTD or maximum administered ...

Phase

3.44 miles

Learn More »

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

This study will involve participants with a condition called Follicular NonHodgkin Lymphoma (Follicular Lymphoma). The main purpose of this study is to see if it is safe to give drug Nivolumab before and in combination with drug Rituximab and to see how effective Nivolumab is in patients who have had ...

Phase

3.44 miles

Learn More »

Phase I Study of MIK665 a Mcl-1 Inhibitor in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

The design of this phase I, open label, dose finding study was chosen in order to characterize the safety and tolerability of MIK665 and to determine the Maximal Tolerated Dose(s) (MTD(s)) and/or Recommended Dose(s) for Expansion (RDE(s)). This study will utilize a Bayesian Hierarchical model to guide dose escalation and ...

Phase

3.44 miles

Learn More »